What medications are recommended for an older adult with Alzheimer-type dementia presenting with cognitive decline?

Pharmacological Management of Alzheimer-Type Dementia with Cognitive Decline

For an older adult with Alzheimer-type dementia presenting with cognitive decline, initiate a cholinesterase inhibitor—specifically donepezil 5 mg once daily—as first-line therapy, with the goal of slowing cognitive and functional deterioration. 1

---

Initial Assessment Before Starting Medication

Before prescribing any cognitive-enhancing medication, you must systematically rule out reversible contributors that can masquerade as or worsen dementia:

• Laboratory workup is essential: Obtain a complete metabolic panel, thyroid function tests (TSH, free T4), vitamin B12, folate, liver function tests, and complete blood count to identify treatable metabolic causes of cognitive impairment 2
• Screen for depression: Late-onset major depressive disorder frequently mimics dementia and requires identification before initiating cholinesterase inhibitors 1
• Medication review: Identify and discontinue anticholinergic agents (diphenhydramine, oxybutynin, cyclobenzaprine) that worsen confusion and cognitive function 2, 1
• Neuroimaging is recommended but not mandatory before starting treatment: Brain CT or MRI should be obtained to detect structural lesions (subdural hematoma, tumor, normal-pressure hydrocephalus, stroke) that require different management, but symptomatic therapy can begin while imaging is pending if acute reversible causes have been clinically excluded 1

---

First-Line Pharmacological Treatment: Cholinesterase Inhibitors

Donepezil (Preferred Agent)

Donepezil is the preferred initial cholinesterase inhibitor due to once-daily dosing, excellent tolerability, and the absence of hepatotoxicity. 1

• Starting dose: 5 mg once daily, taken with food to minimize gastrointestinal side effects 1
• Titration: After 4–6 weeks, increase to 10 mg once daily if the 5-mg dose is well tolerated; the higher dose provides additional cognitive and functional benefit 1
• Expected timeline for benefit: A full efficacy assessment requires 6–12 months of continuous therapy; do not discontinue prematurely 1
• Assessment of response: Use physician global impression, caregiver reports of functional and behavioral changes, and detailed cognitive testing (MMSE or MoCA alone are relatively insensitive to treatment effects) 1

Alternative Cholinesterase Inhibitors

If donepezil is not tolerated or contraindicated, consider:

• Rivastigmine: Start 1.5 mg twice daily with food, increase by 1.5 mg twice daily every 4 weeks as tolerated, maximum 6 mg twice daily 2, 1
• Galantamine: Start 4 mg twice daily, increase to 8 mg twice daily after 4 weeks, may increase to 12 mg twice daily based on tolerability 2, 1, 3
• No cholinesterase inhibitor has proven superiority over another; switching is reasonable only if the current agent is not tolerated 1

Common Pitfalls to Avoid

• Do not stop therapy before 6–12 months unless side effects are intolerable or the patient continues to decline at the pre-treatment rate 1
• Do not rely solely on MMSE scores to assess treatment response; brief mental status tests are insensitive to cholinesterase inhibitor effects 1
• Gastrointestinal side effects (nausea, vomiting, diarrhea) are common initially but can be minimized by taking medication with food and using gradual dose titration 1
• An early increase in agitation may occur during the first few weeks but typically resolves 1

---

Second-Line Treatment: Adding Memantine for Continued Decline

If cognitive and functional decline continues after 6–12 months on optimized donepezil (10 mg/day), add memantine 20 mg/day while continuing the cholinesterase inhibitor. 1, 4

• Memantine is FDA-approved for moderate to severe Alzheimer's disease and provides additional benefit when combined with donepezil 1, 4
• Dosing: Start memantine 5 mg once daily, increase by 5 mg weekly in divided doses to reach the target of 20 mg/day (10 mg twice daily) 1
• Renal adjustment: In severe renal impairment (creatinine clearance ≈30 mL/min), reduce the target dose to 5 mg twice daily (10 mg/day total) 1
• Evidence for combination therapy: Adding memantine to donepezil produces statistically significant improvements of approximately 3.4 points on cognitive scales and 1.4 points on activities-of-daily-living scales compared with donepezil alone 1

---

Safety Profile and Monitoring

Donepezil Safety

• No hepatotoxicity: Unlike tacrine, donepezil does not require liver function monitoring 1
• Serious adverse events: No statistically significant difference versus placebo aside from expected cholinergic side effects (nausea, vomiting, diarrhea) 1
• Withdrawal rates: 5–20% of patients discontinue due to adverse events, comparable to placebo rates of 7–13% 1
• Cardiac considerations: Assess for bradyarrhythmias or sick sinus syndrome, as cholinesterase inhibitors can exacerbate conduction abnormalities 1

Memantine Safety

• Common adverse effects: Nausea, dizziness, diarrhea, and agitation 1
• Discontinuation rates: 9–12% due to adverse effects, comparable to placebo rates of 7–13% 1
• Combination therapy is well tolerated: No increase in serious adverse events when memantine is added to donepezil 1

---

Realistic Expectations and Treatment Goals

• Approximately 20–35% of patients achieve clinically meaningful improvement, roughly equivalent to delaying cognitive decline by one year 1
• The majority of patients experience stabilization (slower decline) rather than improvement 1
• Cholinesterase inhibitors do not cure or reverse dementia; they temporarily slow the rate of decline 1
• Discuss these realistic expectations with patients and families before initiating treatment to avoid disappointment 1

---

Discontinuation Criteria

Stop cholinesterase inhibitor therapy if:

• Persistent adverse effects that do not resolve despite dose adjustment 1
• Continued decline at the pre-treatment rate after a 6–12 month trial at optimal dosing 1
• Poor medication adherence that cannot be improved 1

---

Adjunctive Considerations

• Vitamin E (2,000 IU daily) may slow progression of functional symptoms and is recommended as adjunct therapy by expert consensus 1
• Non-pharmacological interventions (structured routines, environmental modifications, caregiver education) should be implemented alongside medication 1
• Vascular risk factor control (hypertension, diabetes, hyperlipidemia) is essential, as vascular factors can accelerate cognitive decline 1